News Precision psychiatry push starts in Europe As geopolitical tensions ratchet up around the world, an initiative has been launched to drive improvements in diagnostic accuracy and precision care.
News Alto raises $120m for resistant depression programme Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.
Patients The critical role pharmacists play in continuity of care for... One recommended approach to enhancing continuity in BD-I treatment is to deploy coordinated care teams.
News Compass points to strong psilocybin data in depression Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.
News Helus' psychedelic drug DMT 'could help treat depression' Helus' psychedelic derived from ayahuasca, a brew used in shamanistic rituals in South America, has shown promise as a treatment for depression.
R&D The role of the opioid pathway in schizophrenia and bipolar ... Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate.
News Novartis snaps up PI3Kα breast cancer drug in $3bn deal Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.